From: Cost-effectiveness of enzyme replacement therapy for Fabry disease
ICER based on years free of end-organ damage, in € | ICER based QALYs, in € | |||
---|---|---|---|---|
Discounted | Undiscounted | Discounted | Undiscounted | |
Base case typical patient | 3,318,239 | 6,560,885 | 3,282,252 | 6,065,529 |
1. start ERT at 40 years | 3,662,891 | 12,996,662 | 2,158,245 | 7,637,076 |
2. lower QoL during the natural course | - | - | 509,719 | 1,226,674 |
3. course of disease in patients with the classical phenotype only | 3,274,869 | 6,280,356 | 3,015,385 | 5,575,064 |
4. ACE-ARB during natural course | 293,213,929 | 566,675,324 | 11,559,105 | 21,223,686 |
5. No ERT in case of 2 complications | 3,307,363 | 6,529,644 | 3,271,494 | 6,036,644 |
6. including indirect costs of production loss | 3,320,374 | 6,568,971 | 3,284,265 | 6,073,006 |